MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Venture Capital: *Investment Round
Venture Capital: Series A
Clearside Biomedical, Inc. (NASDAQ: CLSD)*
Organization & Developments: Clearside Biomedical
Parents
Clearside Biomedical, Inc. (NASDAQ: CLSD)*
Children
*Plans to use it for a drug it is developing to treat macular edema, or swelling of the retina, and retinal vein occlusion
*SCS injection platform, utilizing proprietary SCS Microinjector, enables in-office, repeatable, non-surgical procedure for delivery of wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
2012: Owns the rights to a micro-needle used to deliver drugs to the back of the eye and the retina that was developed by scientists at Emory University and the Georgia Institute of Technolog Read more here: http://www.newsobserver.com/2012/01/05/1753645/clears
2018: Clearside Biomedical Clears Hurdle For Late-Stage Eye Disease Study - Clearside Biomedical (NASDAQ:CLSD)
2018: Clearside Biomedical shares surge 53% premarket on news of positive trial of eye disease treatment
2018: Clearside Biomedical: Buy Or Sell Before 2018 Catalysts - Clearside Biomedical (NASDAQ:CLSD)
2018: Clearside Biomedical: Upside Into Q4 Data And NDA Submission - Clearside Biomedical (NASDAQ:CLSD)
2018: Positive top-line data from its pivotal Phase 3 PEACHTREE trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis
2021: Circling Back On Clearside Biomedical
2022: Clearside Biomedical (CLSD) Investor Presentation - Slideshow_ seekingalpha.com
Jumps
*Key People: Clearside Biomedical
Finance & Acquisitions: Clearside Biomedical